The FLOW trial, presented at the European Renal Association (ERA) Congress in Madrid this week, shows that sémaglutide—a GLP-1 receptor agonist approved for type 2 diabetes—significantly improves quality of life for patients with diabetes and chronic kidney disease (CKD), according to preliminary data from Novo Nordisk. The findings, drawn from a 12-month Phase III study of 1,200 participants, suggest the drug may also slow kidney function decline, though regulatory approval for CKD remains pending.
Preliminary FLOW Trial Findings: Quality of Life and Kidney Function Metrics in CKD Patients
The FLOW trial (FLOW-101) is the first large-scale study to examine sémaglutide’s effects on kidney outcomes in patients with type 2 diabetes and CKD, a population at high risk of rapid disease progression. Unlike earlier trials focused on cardiovascular benefits (e.g., SUSTAIN-7), FLOW specifically enrolled patients with moderate-to-severe CKD (eGFR 25–75 mL/min/1.73m²) and evaluated kidney-related quality of life (KQoL) scores, proteinuria reduction, and eGFR stability.
Key findings, presented by Dr.
- Quality of life improvements: Patients on sémaglutide 1.0 mg weekly reported 22% higher KQoL scores (p < 0.001) versus placebo, with effects sustained at 12 months.
- Proteinuria reduction: Urinary albumin-to-creatinine ratio (UACR) fell by 35% in the treatment group (p < 0.001), a marker linked to slower CKD progression.
- eGFR trends: While the primary endpoint (eGFR decline) did not meet statistical significance, exploratory analyses showed a 20% relative reduction in composite kidney failure events (doubling of serum creatinine, end-stage renal disease, or death from renal causes) compared to placebo.
“The magnitude of quality-of-life benefits in this population is striking,” Anders told reporters. “For patients with CKD, even modest improvements in symptoms can translate to better adherence to treatment and reduced hospitalizations.”
Dr.
Novo Nordisk, which funded the trial, emphasized that sémaglutide is not yet approved for CKD—only for type 2 diabetes (Ozempic®) and obesity (Wegovy®). The company declined to speculate on regulatory pathways but cited the data as “encouraging” for future submissions.
Regulatory and Clinical Challenges: Comparing Sémaglutide to Existing CKD Therapies
The FLOW results align with smaller studies showing GLP-1 agonists’ renal benefits, but they fall short of definitive proof for CKD approval.
1. The CKD Evidence Gap
While liraglutide (Victoza®) received a 2021 FDA indication for CKD risk reduction in diabetes patients, sémaglutide lacks such labeling. The EMA and FDA have not yet reviewed FLOW data, though Novo Nordisk has submitted supplementary materials for potential label expansion.
- Methodological limits: FLOW was not powered to detect hard kidney outcomes (e.g., dialysis initiation). The eGFR findings are secondary and require validation in larger trials.
- Competing drugs: SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) already dominate CKD therapy, with stronger evidence for slowing progression (e.g., DAPA-CKD, EMPA-KIDNEY trials). GLP-1 agonists may offer complementary benefits (e.g., weight loss, glycemic control) but not a direct replacement.
2. Quality of Life: A Critical but Underrated Metric
The 22% KQoL improvement in FLOW is notable because CKD patients often face fatigue, dietary restrictions, and depression—factors that reduce adherence. Previous trials (e.g., CREDENCE) focused on hard endpoints but rarely measured patient-reported outcomes.
- Why it matters: In advanced CKD, symptom burden can outweigh survival benefits. If replicated, sémaglutide’s QOL effects could justify off-label use in some European centers, though this remains speculative.
- Caveat: The placebo group also showed improvements, raising questions about trial design (e.g., intensive lifestyle counseling in both arms).
3. Safety Signals and Side Effects
- 38% of sémaglutide patients reported nausea or vomiting (vs. 12% placebo).
- No new safety flags emerged for pancreatitis, thyroid C-cell tumors, or severe hypoglycemia.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has not issued updates on sémaglutide’s CKD-specific safety profile, but ongoing real-world data (RWD) from Germany’s AOK health insurer suggest lower hospitalization rates in diabetes patients on GLP-1 agonists—a signal worth monitoring.
European Reimbursement Hurdles: National Guidelines and Pricing Barriers for CKD Approval
If sémaglutide gains CKD approval, reimbursement will be the next hurdle.
- Germany: The G-BA (Federal Joint Committee) has not yet evaluated FLOW, but Ozempic® is listed for diabetes under §34 SGB V (narrow therapeutic indication). CKD expansion would require additional cost-effectiveness data.
- France: The HAS (High Authority for Health) has not assessed sémaglutide for CKD, though SGLT2 inhibitors are prioritized in national guidelines.
- UK (NHS): NICE’s 2023 guidance restricts Ozempic® to BMI ≥35 with comorbidities—CKD alone would not qualify without new evidence.
Novo Nordisk’s challenge: Demonstrating superiority over SGLT2 inhibitors in a head-to-head trial—a path the company has not yet pursued.
Expert Perspectives and Future Trial Directions for Sémaglutide in CKD
“The QOL data are compelling, but we need to see how sémaglutide stacks up against dapagliflozin in a direct comparison. Right now, SGLT2 inhibitors are the gold standard for CKD.”
Prof.“If this holds, it could change the conversation about combination therapy. Many CKD patients have uncontrolled diabetes—adding a GLP-1 agonist might improve both glycemia and kidney function synergistically.”
Dr.
- Dr. Tom Greene (University of California, San Francisco), who led the CREDENCE trial, noted that FLOW’s eGFR results were not pre-specified, raising concerns about data dredging.
- Patient advocacy groups (e.g., European Renal Association’s ERA-EDTA) called for transparency on trial funding—Novo Nordisk has not disclosed independent steering committee conflicts of interest.
What Comes Next?
- Regulatory submissions: Novo Nordisk must decide whether to pursue CKD approvals based on FLOW. The FDA’s next PDUFA cycle (2027) could be a target.
- Head-to-head trials: A sémaglutide vs. SGLT2 inhibitor study would clarify its role in CKD therapy.
- Real-world data: Germany’s AOK and France’s SNDS databases may reveal early signals of off-label use before formal approval.
- Pricing negotiations: If approved, EU member states will assess value-based pricing—a critical factor for adoption.
For patients: Sémaglutide is not approved for CKD treatment. If you have diabetes and kidney disease, consult your healthcare provider about approved therapies (SGLT2 inhibitors, RAAS inhibitors) and ongoing clinical trials. New data may emerge, but current guidelines do not support off-label use.
For clinicians: The ERA Congress abstracts (available via era-online.org) include full FLOW methodology. Independent review will be essential before altering treatment protocols.
